Table 2.
Comparison of characteristics between the lymphadenopathy and non-lymphadenopathy.
| Characteristics | Lymphadenopathy (n = 202) |
Non-lymphadenopathy (n = 211) |
p Value |
|---|---|---|---|
| Mean age (years) * | 44 ± 11 (17–79) | 52 ± 10 (24–80) | <0.001 |
| Age group | <0.001 | ||
| ≤40 years | 67 (33) | 28 (13) | |
| >40 years | 135 (67) | 183 (87) | |
| Sex | 0.106 | ||
| Women | 200 (99) | 203 (96) | |
| Men | 2 (1) | 8 (4) | |
| Mean interval (days) * | 20 ± 14 (2–80) | 32 ± 19 (1–82) | <0.001 |
| Interval group | <0.001 | ||
| 1–14 days | 77 (38) | 44 (21) | |
| 15–28 days | 82 (41) | 49 (23) | |
| 29–42 days | 29 (14) | 63 (30) | |
| ≥43 days | 14 (7) | 55 (26) | |
| Site | 0.341 | ||
| Left arm | 188 (93) | 201 (95) | |
| Right arm | 14 (7) | 10 (5) | |
| Vaccine brand | <0.001 | ||
| Pfizer | 182 (90) | 148 (70) | |
| AstraZeneca | 5 (3) | 59 (28) | |
| Moderna | 15 (7) | 4 (2) | |
| Vaccine type | <0.001 | ||
| mRNA | 197 (98) | 152 (72) | |
| Vector | 5 (2) | 59 (28) | |
| Dose | <0.001 | ||
| 1st | 98 (48) | 58 (28) | |
| 2nd | 104 (52) | 153 (73) | |
| Axillary symptom | 0.003 | ||
| Yes | 8 (4) | 0 (0) | |
| No | 194 (96) | 211 (100) |
Note: unless otherwise specified, data represent the number of patients and data in parentheses are percentages. * Data are presented as means ± standard deviation; data in parentheses represent the ranges.